Canine faecal microbiota transplantation: protocols and outcomes

The canine gut microbiome is an active part of gastrointestinal health, not a simple list of “good” and “bad” organisms. Changes in microbial communities may accompany chronic enteropathy, dietary intolerance, antimicrobial exposure and inflammatory disease. Interpreting those changes requires clinical context, because sequencing results do not automatically identify the cause of a patient’s diarrhoea.

Canine fecal microbiota transplantation involves transferring a screened donor community into a recipient’s gastrointestinal tract to influence this ecosystem. Interest has grown among veterinary teams, but the technique remains an evolving adjunct rather than a standardised treatment. Published protocols differ in donor selection, sample preparation, delivery route, pretreatment and follow-up.

Hill’s ActivBiome supports continuing education through expert presentations, on-demand webinar recordings and downloadable resources. Its broader collaboration with researchers and institutions including Harvard T.H. Chan School of Public Health, Texas A&M University and the University of Vienna places canine and feline microbiome science within an international research context.

For Australian veterinarians, that evidence must be adapted to local medicine regulation, laboratory access, donor logistics and owner expectations. Clear endpoints and informed consent are essential, especially where chronic gastrointestinal disease has already prompted repeated dietary changes, medication trials and diagnostic spending.

The clinical rationale

Faecal transplantation is most relevant to selected dogs with persistent or recurrent enteropathy, particularly when conventional management has not achieved an acceptable response. It should not substitute for investigating mechanical obstruction, parasites, neoplasia, exocrine pancreatic insufficiency or other treatable problems. Acute diarrhoea in otherwise stable dogs usually needs supportive care and a cause-based plan, not immediate transplantation.

Dysbiosis describes an altered microbial community, but no single assay reliably labels a patient as suitable or unsuitable. History, diet, medication exposure, faecal microscopy and culture, targeted PCR and other investigations should guide case selection. A microbiome profile can support a hypothesis without replacing clinical reasoning.

Prebiotics, targeted diets and postbiotics may form part of the broader plan. The evidence summary on postbiotics in veterinary practice is useful context, but a defined postbiotic product is not equivalent to transferring a living microbial community.

Donor screening and sample handling

Donor health is the foundation of safety. Canine donors should have a normal examination, up-to-date vaccination and parasite prevention, no recent antimicrobial exposure and no signs of gastrointestinal disease. Their travel, diet and medication history also matter, particularly when dogs have travelled beyond their usual Australian environment.

Screening should consider enteric bacteria, parasites, antimicrobial-resistance patterns and other transmissible agents, recognising that asymptomatic carriage occurs. Human-derived donors add infectious-disease screening and governance requirements. Consent, chain-of-custody documentation, biosafe transport and disposal of unused material should follow the receiving clinic’s approved procedures.

Faeces may be prepared fresh or frozen for administration, but handling affects viable organisms and consistency between protocols. Collection devices, mixing, strain size, storage temperature and transport time need validation under the chosen method. For practices outside major metropolitan centres, overnight courier schedules and access to suitable laboratory processing can limit comparability.

Practical treatment protocols

A practical protocol begins with stabilisation: correct dehydration and electrolyte deficits, address hypoalbuminaemia where indicated, and review oral medication that could obscure interpretation. Antibiotic pretreatment has been used in some protocols, yet its value, choice and timing are not settled; dogs with severe sepsis need appropriate antimicrobial therapy without delay.

Faecal material is commonly blended with a sterile diluent, strained and delivered rectally, while some specialist protocols use colonoscopic administration. Dose, frequency, pretreatment, anaesthetic use and the need for repeat procedures vary between studies and clinics. Frozen preparations and commercial faecal banks may improve logistics, although processing can alter the community.

Repeated administrations are sometimes used when the first response is incomplete. Any protocol should specify clinical endpoints, stop criteria and a review date, with owners informed that benefits may be partial or transient. If vomiting, bleeding, pain or weight loss worsens, transplantation should pause while the underlying disease is reassessed.

Evidence, outcomes and monitoring

Current evidence in dogs mainly comprises case reports, small cohorts and experimental studies, with limited randomised controlled-trial data. Some refractory cases have improved faecal consistency, appetite and body weight, and some owners have reported reduced medication needs. These signals justify carefully selected use, but they do not establish a cure rate.

Outcomes should be measured with repeatable clinical outcomes: faecal score, body weight, appetite, medication use and quality-of-life changes. Microbiome sequencing can describe ecological shifts, but it cannot by itself demonstrate resolution of disease. Long-term safety, optimal donor matching and the durability of responses remain important unanswered questions.

Where transplantation is used, it should sit alongside a stabilised diet and appropriate medical management, rather than replacing them. Published results can vary with disease severity, recipient selection, donor quality and concurrent treatment. Owners should understand these uncertainties before treatment begins, and compliance with the agreed follow-up plan is central to interpreting any change.

Implementation in Australia

Australian implementation begins with a regulatory review. Canine faecal microbiota transplantation is not a routine registered veterinary treatment, and the applicable pathway may involve the APVMA, the Therapeutic Goods Administration, state and territory legislation, institutional biosafety and waste rules. A service should document its intended use, quality controls, informed consent and adverse-event procedures before accepting material.

Customs and biosecurity also matter if donor material or reference samples cross borders. Australian Border Force and the Department of Agriculture, Fisheries and Forestry should be consulted before import, and material from overseas must not be assumed to satisfy Australian pathogen controls. For clinics in Melbourne, Sydney, Brisbane and Perth, donor transport distances, courier timing and access to anaerobic or metagenomic laboratories vary considerably.

Hill’s ActivBiome’s recorded webinar sessions provide a structured way for Australian veterinary teams to review current evidence and support continuing professional development, with downloadable resources and participation certificates available. Local interpretation should still account for Australia’s pet-food market, where premium dry, wet and fresh formats are widely available, and for the availability of specialist dietetic support in major cities.